替奈普酶在老年大血管闭塞患者中的安全性与有效性:EXTEND-IA TNK试验汇总分析
该研究汇总分析EXTEND-IA TNK随机对照试验(n=502),比较替奈普酶0.25 mg/kg、0.40 mg/kg与阿替普酶0.90 mg/kg在年龄>80岁大血管闭塞患者中的疗效与安全性。结果显示,在>80岁患者(n=137)中,替奈普酶0.25 mg/kg较0.40 mg/kg改善90天mRS(中位3 vs 4,acOR 2.70,95%CI 1.23-5.94)并降低死亡率(acOR 0.34,95%CI 0.13-0.91),且较阿替普酶改善90天mRS(中位3 vs 4,acOR 2.28,95%CI 1.03-5.05)。
要点
- 在>80岁大血管闭塞患者中,替奈普酶0.25 mg/kg较0.40 mg/kg改善90天mRS并降低死亡率。
- 替奈普酶0.25 mg/kg较阿替普酶0.90 mg/kg改善>80岁患者90天mRS。
- ≤80岁患者中三种溶栓方案90天mRS、死亡率及症状性颅内出血无差异。
核心结论
- 在>80岁大血管闭塞卒中患者中,血管内治疗前给予替奈普酶0.25 mg/kg与更好的90天功能结局和更低的死亡率相关;在≤80岁患者中未观察到各剂量间的差异。
研究设计与样本
- EXTEND-IA TNK随机对照试验的汇总分析,共纳入502例成人缺血性卒中患者,病因为颅内颈内动脉、大脑中动脉或基底动脉闭塞,症状发作4.5小时内就诊。
主要发现
- 在>80岁患者(n=137)中,替奈普酶0.25 mg/kg较0.40 mg/kg改善90天mRS(中位3 vs 4,acOR 2.70,95%CI 1.23-5.94)并降低死亡率(acOR 0.34,95%CI 0.13-0.91)。
- 在>80岁患者中,替奈普酶0.25 mg/kg较阿替普酶改善90天mRS(中位3 vs 4,acOR 2.28,95%CI 1.03-5.05)。
- 在>80岁患者中,阿替普酶与替奈普酶0.40 mg/kg之间未检测到90天mRS或死亡率的差异。
- 症状性颅内出血在接受替奈普酶0.40 mg/kg的4例患者、接受阿替普酶的1例患者和接受替奈普酶0.25 mg/kg的0例患者中观察到。
- 在≤80岁患者中,替奈普酶0.25 mg/kg、阿替普酶和替奈普酶0.40 mg/kg之间未观察到90天mRS、死亡率或症状性颅内出血的差异。
关键数值与推荐
- 替奈普酶0.25 mg/kg、替奈普酶0.40 mg/kg、阿替普酶0.90 mg/kg。
- 年龄分层:>80岁与≤80岁。
- 主要结局:90天改良Rankin量表(mRS)评分、全因死亡率、症状性颅内出血。
- 调整因素:基线NIH卒中评分、年龄、症状发作至穿刺时间。
- 证据等级:本研究提供II级证据,表明在>80岁大血管闭塞卒中患者中,血管内治疗前给予替奈普酶0.25 mg/kg与更好的90天功能结局和降低的死亡率相关。
临床怎么用
- 作者认为,在>80岁大血管闭塞卒中患者中,血管内治疗前给予替奈普酶0.25 mg/kg与更好的90天功能结局和更低的死亡率相关。
- 作者未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Detailed study of tenecteplase (TNK) in patients older than 80 years is limited. The objective of our study was to assess the safety and efficacy of TNK at 0.25 and 0.40 mg/kg doses in patients older than 80 years with large vessel occlusion. METHODS: We performed a pooled analysis of the EXTEND-IA TNK randomized controlled trials (n = 502). Patients were adults presenting with ischemic stroke due to occlusion of the intracranial internal carotid, middle cerebral, or basilar artery presenting within 4.5 hours of symptom onset. We compared the treatment effect of TNK 0.25 mg/kg, TNK 0.40 mg/kg, and alteplase 0.90 mg/kg, stratifying for patient age (>80 years). Outcomes evaluated include 90-day modified Rankin Scale (mRS) score, all-cause mortality, and symptomatic ICH. Treatment effect was adjusted for baseline NIH Stroke Score, age, and time from symptom onset to puncture via mixed effects proportional odds and logistic regression models. RESULTS: In patients >80 years (n = 137), TNK 0.25 mg/kg was associated with improved 90-day mRS (median 3 vs 4, adjusted common odds ratio (acOR) 2.70, 95% CI 1.23-5.94) and reduced mortality (acOR 0.34, 95% CI 0.13-0.91) vs 0.40 mg/kg. TNK 0.25 mg/kg was associated with improved 90-day mRS (median 3 vs 4, acOR 2.28, 95% CI 1.03-5.05) vs alteplase. No difference in 90-day mRS or mortality was detected between alteplase and TNK 0.40 mg/kg. Symptomatic ICH was observed in 4 patients treated with TNK 0.40 mg/kg, 1 patient treated with alteplase, and 0 patients treated with TNK 0.25 mg/kg. In patients ≤80 years, no differences in 90-day mRS, mortality, or symptomatic ICH were observed among TNK 0.25 mg/kg, alteplase, and TNK 0.40 mg/kg. DISCUSSION: TNK 0.25 mg/kg was associated with improved 90-day mRS and lower mortality in patients older than 80 years. No differences among the doses were observed in younger patients. TRIAL REGISTRATION INFORMATION: NCT02388061, NCT03340493. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that tenecteplase 0.25 mg/kg given before endovascular therapy in patients >80 years old with large vessel occlusion stroke is associated with better functional outcomes at 90 days and reduced mortality when compared to tenecteplase 0.40 mg/kg or alteplase 0.90 mg/kg.
引用
- Yogendrakumar V, Churilov L, Mitchell PJ, et al. Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion: A Pooled Analysis of the EXTEND-IA TNK Trials. Neurology. 2022. PMID: 35017305. doi:10.1212/WNL.0000000000013302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。